stockportfolio.pro
Stocks / BMRN vs PODD
BMRN vs PODD
BioMarin Pharmaceutical Inc. and Insulet Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioMarin Pharmaceutical Inc. (BMRN) | Insulet Corporation (PODD) | |
|---|---|---|
| Market cap | $10.9B | $10.3B |
| Revenue (latest FY) | $3.22B | $2.71B |
| Net income (latest FY) | $348.90M | $247.10M |
| Revenue growth (5y CAGR) | 11.6% | 24.5% |
| Net margin | 10.8% | 9.1% |
| Return on equity | 5.7% | 16.3% |
| P/E ratio | 40.4 | 34.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMRN — free Open PODD — freeFrequently asked questions
Which is bigger, BMRN or PODD?
BioMarin Pharmaceutical Inc. is larger by market capitalization — $10.9B versus $10.3B.
Which grows faster, BMRN or PODD?
Over the last five fiscal years, Insulet Corporation grew revenue faster — 24.5%/yr versus 11.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.